Plain-English translation of NCT04567511 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called Hemlibra () to see if it can help people with mild hemophilia A—a bleeding disorder caused by low levels of clotting factor VIII—control their bleeding episodes better. The study will track how well this treatment works, how safe it is, and whether it improves patients' quality of life and joint health over time.
Hemophilia A can cause painful bleeding into joints and muscles, which over time can damage the joints and affect how people live their daily lives. This medication works in a new way compared to standard treatments, and researchers want to understand if this treatment can be effective and safe specifically for people with mild hemophilia A.
You likely qualify if…
You likely don't qualify if…
You will receive regular injections of the medication under your skin and visit the clinic multiple times to have blood tests, answer health questionnaires, and report any bleeding episodes you experience. The study will track your bleeding patterns, joint health, and overall quality of life over the course of the trial. The research team will carefully monitor you for any side effects and will withdraw you from the study if you develop an inhibitor to factor VIII.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States